Cite
HARVARD Citation
Panaccione, R. et al. (n.d.). A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. Journal of the Canadian Association of Gastroenterology. pp. 43-45. [Online].